Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 2/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506574 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10GAASMN1; SMN2 | |
| SCHEMBL4741554 | 0.85 | ALDH1A1 (0.40) | ALDH1A1KDM4EGAASMN1; SMN2LMNA | |
| SCHEMBL181067 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KDM4EHSD17B10GAASMN1; SMN2 | |
| SCHEMBL22889869 | 0.83 | TSHR (0.58) | ALDH1A1KDM4EHSD17B10GAALMNA | |
| SCHEMBL25044297 | 0.83 | LMNA (0.46) | ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL16958922 | 0.83 | LMNA (0.46) | ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL16953909 | 0.83 | LMNA (0.46) | ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL2383149 | 0.83 | CA12 (0.48) | ALDH1A1KDM4EHSD17B10GAASMN1; SMN2 | |
| SCHEMBL14050225 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EHSD17B10GAASMN1; SMN2 | |
| SCHEMBL4825804 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| EP-4452918-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4288429-A1 | LACTAMS AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230079990-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-7381722-B2 | Tetracyclic amino and carboxamido compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381722-B2 | Tetracyclic amino and carboxamido compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| CN-101023063-A | Azine-carboxamides as anti-cancer agents | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | CN | disclosed |
| WO-2007025009-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| CN-1169792-C | Substituted vinylpyridine derivatives and medicaments containing them | ������ҩ��ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| EP-0685478-B1 | QUINOLINE DERIVATIVES | UBE INDUSTRIES (JP) | 2001-10-24 | — | — | EP | disclosed |
| CN-1206407-A | Substituted vinylpyridine derivatives and medicaments containing them | SS PHARMACEUTICAL CO (JP) | 1999-01-27 | — | — | CN | disclosed |
| US-5591752-A | LEUKOTRIENE ANTAGONIST, ANTIALLERGEN, ANTIINFLAMMATORY AGENT, DIBENZ(B,E)OXEPINE | UBE INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| EP-0685478-A1 | QUINOLINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | ALDH1A1 4468/4885KDM4E 2197/4885HSD17B10 3733/4885 |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | ALDH1A1 4354/4885KDM4E 1087/4885HSD17B10 3231/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | ALDH1A1 137/4885KDM4E 2660/4885HSD17B10 972/4885 |
| US-20230079990-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | ALDH1A1 4354/4885KDM4E 1087/4885HSD17B10 3231/4885 |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | ALDH1A1 431/4885KDM4E 4051/4885HSD17B10 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.